Korean J Urol.  2006 Sep;47(9):974-977. 10.4111/kju.2006.47.9.974.

Correlation of Clinical Progress and Serum Prostate Specific Antigen in the Treatment of Chronic Prostatitis

• Kim DW
• Noh AS
• Park SS

• KMID: 2294094
• DOI: http://doi.org/10.4111/kju.2006.47.9.974

Abstract

Purpose
We compared the baseline and post-treatment serum prostate specific antigen levels (s-PSA), the expressed prostatic secretion (EPS) and the chronic prostatitis symptom index (CPSI). We wanted to determine whether the serum PSA level could be used as a biochemical marker for checking the progress of patients with chronic prostatitis.
Materials and Methods
Of the patients who diagnosed with chronic prostatitis, we respectively reviewed the records of 48 men who were under 50 years old and who presented with a serum PSA level lower than 4ng/ ml (group P). As a control group (group N), we used the s-PSA data obtained from 2,787 men under 50 years old who had no evidence for lower urinary infection, and these men were seen at a serial screening program of a primary health clinic. After the treatment with antibiotics and nonsteroidal anti-inflammatory agents, the serum PSA and EPS were rechecked every 4 weeks. The National Institutes of Health (NIH)-CPSI scores were rechecked after 8 weeks.
Results
There are no different at mean age (group P vs N; 41.1 vs 41.1 years old). The baseline average serum PSA in group P was 1.53+/-0.73 ng/ml, and that in group N was 0.85 0.81ng/ml; the difference was significant (p=0.001). After 8 weeks of treatment, the average post-treatment serum PSA level was significantly decreased to 1.22+/-0.59ng/ml (p<0.05) and the leukocyte count in the EPS was also significantly decreased (p<0.05). The total NIH-CPSI score was significantly improved (p<0.05).
Conclusions
These data suggest that serum PSA is increased in chronic prostatitis patients. Antibiotics and nonsteroidal anti-inflammatory treatment can relief patients' symptoms as well as decrease the serum PSA for chronic prostatitis after 8 weeks. Therefore, serum PSA could be used as a diagnostic factor in determining the patients' progress with employing the CPSI score and EPS results.

Keyword

Prostate-specific antigen; Prostatitis

MeSH Terms

Anti-Bacterial Agents
Anti-Inflammatory Agents, Non-Steroidal
Biomarkers
Humans
Leukocyte Count
Male
Mass Screening
Middle Aged
National Institutes of Health (U.S.)
Prostate*
Prostate-Specific Antigen*
Prostatitis*
Anti-Bacterial Agents
Anti-Inflammatory Agents, Non-Steroidal
Prostate-Specific Antigen

Reference

1. Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, Litwin MS. Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. J Urol. 2002. 168:593–598.

2. Cho IR, Kim KJ, Park SS, Choi HS. PSA and prostatitis in men under 45 years old. Korean J Urol. 1998. 39:633–637.

3. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995. 154:407–413.

4. Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology. 1999. 54:229–233.

5. Roberts RO, Lieber MM, Bostwick DG, Jacobsen SJ. A review of clinical and pathological prostatitis syndromes. Urology. 1997. 49:809–821.

6. Meares EM Jr. Prostatitis. Med Clin North Am. 1991. 75:405–424.

7. Doble A. Chronic prostatitis. Br J Urol. 1994. 74:537–541.

8. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979. 17:159–163.

9. Stamey TA, Yang N, Hay HR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987. 317:909–916.

10. Brawn PN, Speights VO, Kuhl D, Riggs M, Spiekerman AM, McCard RG, et al. Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer. 1991. 68:1592–1599.

11. Neal DE Jr, Clejan S, Sarma D, Moon TD. Prostate-specific antigen and prostatitis. I, Effect of prostatitis on serum PSA in the human and nonhuman primate. Prostate. 1992. 20:105–111.

12. Pansadoro V, Emiliozzi P, Defidio L, Scarpone P, Sabatini G, Brisciani A, et al. Prostatic-antigen and prostatitis in men under fifty. Eur Urol. 1996. 30:24–27.

13. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993. 150:379–385.

14. Potts JM. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen. J Urol. 2000. 164:1550–1553.

15. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostatic specific antigen. J Urol. 2002. 167:1723–1726.

16. Rho TH, Lee JG, Nam SK. The effect of the treatment of prostatitis on the serum prostate specific antigen levels and the frequency of prostate biopsies. Korean J Urol. 2002. 43:847–851.

17. Cheong JY, Cheon SH, Park RJ, Oh CS, Kim JH. The change of prostate specific antigen after treatment in chronic prostatitis associated with elevated serum prostate specific antigen. Korean J Urol. 2003. 44:819–822.